Tag
Contract Research
3 articles
Anthem FY26 PAT Up 31% to ₹5,918 Mn
Anthem Biosciences reported FY26 consolidated revenue of ₹21,243 Mn with 15.2% YoY growth and PAT of ₹5,918 Mn with 31.1% YoY growth.
Q4FY26 revenue grew 26.4% YoY to ₹6,109 Mn with PAT surging 129.8%
Anthem FY26 Revenue Up 15% to ₹21,243 Mn
Anthem Biosciences reported FY26 consolidated revenue of ₹21,243 Mn, a 15.2% YoY growth, with CRDMO business leading at ₹17,727 Mn.
EBITDA for FY26 stood at ₹9,896 Mn with 43.4% margins, while PAT gre
Anthem Biosciences FY26 KPI Disclosure: Revenue Growth, Margins
• Anthem Biosciences discloses audited KPIs for FY26 showing ₹21.24 billion revenue and 15.17% YoY growth.
• Material margin improved to ₹13.12 billion with EBITDA margin at 41.01% and PAT margin at 2